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ABSTRACT  
Allopurinol-induced DRESS Syndrome or Drug Rash with Eosinophilia and Systemic Symptom is a rare but potentially fatal drug reaction. Fever, 
rashes, swelling, and hematologic abnormalities, particularly short-term or long-term injury to one or more organs, have been reported by over 0.4 
percent of patients following the course of medicine. Here, a 54-year-old female patient was admitted to the hospital with complaints of fever, 
purpuric rashes over the body with itching mainly in the oral cavity and lips, and the extent to the upper back and lower limbs for three days. She 
had known complaints of Type 2 Diabetes, Systemic hypertension, Coronary artery disease with recent NSTEMI, Dyslipidaemia, Psychosis (20y), 
and Chronic kidney disease. She had been taking Allopurinol for the past three months for hyperuricemia. Allopurinol treatment stopped while 
topical Steroid treatment started along with supportive therapy. After ten days, the rashes improved significantly, allowing her to leave the hospital. 
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INTRODUCTION 
An enzyme inhibitor, Allopurinol, inhibits Xanthine Oxidase and has 
been effective in reducing urate levels in hyperuricemia patients and 
relieving Gout symptoms permanently [1]. In 1966, the FDA 
approved this drug primarily to treat Gout, Tumour Lysis Syndrome. 
Furthermore, they can prevent calcium nephrolithiasis in 
hyperuricosuria individuals. The primary component that separates 
the purine bases and catalyzes the conversion of hypoxanthine to 
xanthine and xanthine to uric acid is a xanthine oxidase. Uric acid is 
passed through the body regularly. This chemical insufficiency might 
be due to a genetic component, with increased purine nourishment 
ingestion and less catalyst production at some point. Allopurinol 
increased the action of any drug processed by xanthine oxidase [2]. 
Acting as an analog of Hypoxanthine, it was mainly used for Gout 
management by decreasing uric acid production [3].  
Allopurinol is a well-tolerated drug with few adverse drug reactions. The 
mild cutaneous reaction had appeared in almost 2% of patients [3]. But 
Allopurinol-induced Hypersensitivity syndrome (AHS) and Drug Rash 
with Eosinophilia and Systemic Symptom (DRESS) are the rarest but 
most severe hypersensitivity reactions. The researchers estimated that 
one in every 260 patients suffers from DRESS Syndrome as an adverse 
drug reaction of Allopurinol. Within eight weeks of commencing therapy, 
patients had cutaneous responses, fever, eosinophilia, swelling, renal and 
hepatic dysfunction, and hepatic damage [3]. 
The precise mechanism responsible for DRESS Syndrome is 
unknown, but it may represent the genetic association of HLA-
B*58:01 [4]. Although, the most common differential Diagnosis of 
DRESS Syndrome includes Toxic Epidermal Necrosis, Steven-
Johnson Syndrome, Eosinophilia, Still’s Disease, and Kawasaki 
Disease [3]. Skin Biopsy is the gold standard for DRESS Syndrome. 
Discontinuing the substance responsible for its etiology is the first 
step in implementing a supportive treatment strategy based on the 
symptoms [5]. Along with that, steroid therapies are also important. 
The effect of Steroids on the inhibition of Interleukin-5 and 
Eosinophil accumulation and its dramatic improvement in clinical 
symptoms make this therapy more beneficial for the patient [3]. 
Here, we report a case of a 54-year-old female who developed 
DRESS syndrome as a rare side effect of allopurinol treatment. 
CASE REPORT 
A 54-year-old female patient came to the hospital with chief 
complaints of purpuric rashes over the body. Presented with the 
itching for the past three days without raised patches, presence of 
one episode of fever spikes, mild abdominal pain with no history of 
loose stool, vomiting, travel outside, cough and dyspnea. But her legs 
appeared swollen mildly. The patient had no loss of consciousness 
and seizures on admission. The patient had known complaints of 
Type 2 Diabetes mellitus, Systemic hypertension, Coronary artery 
disease with recent NSTEMI, Dyslipidaemia, Psychosis (20 y), 
chronic kidney disease. In addition, the patient was recently 
diagnosed with hyperuricemia and had been taking Allopurinol 100 
mg for the previous three months. The patient was afebrile but had 
several painful lymph nodes after arrival. On general examination, 
the patient was conscious, alert, pallor, no icterus, 
lymphadenopathy, rashes over upper chest, lower limbs, the trunk, 
sides of the ear, arms, purpuric macules on the legs, tremor, crusting 
on lips, and generalized tremors. Blood pressure was 160/80 mmHg. 
Haemoglobin 7.7 g/dl, WBC 2480/cumm, Eosinophil 10%, Platelet 
count 100000/cumm, PCV 23.7%, Serum Urea levels 122.2 mg%, 97 
mg%, and 106 mg% respectively, Serum Creatinine 4.15 mg%, 3.89 
mg%, and 4.9 mg%, and Serum Albumin 3.3 gm% appeared in the 
blood analysis [table 1].  
 
Table 1: Lab parameters 
 Lab parameters  Values 
 Blood pressure  160/80 mmHg 
 Hemoglobin 7.7g/dl 
 Total WBC 2480/cumm 
 Eosinophil 10% 
 Platelet Count 100000/cumm 
 PCV  23.7% 
 Serum Urea Level 122.2 mg%, 96 mg%, and106 mg% 
 Serum Creatinine 4.15 mg%, 3.9 mg% and 4.9 mg% 
 Serum Albumin  3.3g% 
  
The peripheral smear test showed normocytic normochromic 
anemia with microcytic hypochromic RBCs, leukopenia, and 
eosinophilia. It concluded that there was no evidence of dengue 
fever through a dengue test. No significant regional wall motion 
abnormalities on ECHO, good LV/RV systolic function, mild mitral 
valve regurgitation. She was diagnosed with low blood cell counts. 
The nephrologist recommended stopping Allopurinol, Cardivas, and 
Magnesium Valproate after the second day and starting Topical 
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Steroid therapy alongside supportive therapy. Desowen (Desonide) 
for local application and Kenocort 0.1% (Triamcinolone) oromucosal 
paste was used on the first day and continued for ten days for 
discharge medication. 
DISCUSSION 
Allopurinol is an analog of Hypoxanthine, commonly used in clinical 
practice for treating hyperuricemia [3]. Patients receiving 
Allopurinol therapy are at risk of developing Adverse drug reactions 
mainly in the form of DRESS Syndrome (Drug Rash with Eosinophilia 
and Systemic Symptom) [6]. DRESS is an Idiosyncratic 
Hypersensitivity Reaction, characterized by skin rash, fever, lymph 
node enlargement, and multiple organ involvement. Fever, Rashes, 
Multiorgan involvement can be considered the Clinical Triad of 
DRESS Syndrome. In our patient erythematous maculopapular rash 
throughout the body, especially in the oral cavity and lips. It also 
extends to the lower limbs and upper back. The presence of 
excessive eosinophilia was another marker for our patient. Other 
studies reveal that the use of Allopurinol in Renal and 
Cardiovascular disease patients had a significantly higher risk of 
developing hypersensitivity reactions [7]. In this sense, our patient 
was a CKD patient and a CAD patient. Recent NSTEMI, Elevated 
serum urea and serum creatinine level, and Hypoalbuminemia 
indicate that patients had an increased chance of developing 
Hypersensitivity syndrome. In most of the Case Reports, 100-300 
mg/day of Allopurinol causes DRESS Syndrome. The patient was on 
100 mg/day. In addition to the withdrawal of the offending drug 
Allopurinol, Steroid therapies are relevant to concern [8]. For our 
patient, Allopurinol was stopped on the second day of admission to 
the hospital while, the same day, Topical Steroid therapy began 
along with Supportive care. Desowen (Desonide) for local 
application and Kenocort 0.1% (Triamcinolone) oromucosal paste 
were given and continued for ten days for the follow-up. Early 
cessation of the offending drug and Steroid therapy results in a 
better outcome and alleviates the symptoms. Drug use should be 
monitored closely in patients with impaired renal insufficiency and 
liver dysfunction, to the possible risk of developing DRESS 
Syndrome. 
CONCLUSION 
Allopurinol is an FDA-approved urate-lowering agent. In general, this 
medication treats primarily to treat hyperuricemia, gout, and calcium 
nephrolithiasis. Due to the severity of potential side effects, most 
patients experience Fever, Eosinophilia, Multiorgan damage, or other 
Systemic Syndrome. The mainstay treatment for the DRESS Syndrome 
is the early recognition of the culprit drug and its withdrawal, coupled 
with steroidal therapy and supportive treatments. Understanding this 
rare drug reaction could potentially protect our patients and eliminate 
the risk of adverse drug events forever.  
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